When does tenapanor’s product patent expire in the US?
The provided information does not include tenapanor’s US product patent expiry date(s). Without the relevant patent numbers, filing/publication details, or an exclusivity/patent portfolio list, the exact expiry cannot be determined from the details available here.
What do you need to look up to find the exact US expiry date?
To get the correct US “product patent expiry” for tenapanor, you typically need one or more of the following:
- The specific US patent numbers covering the product (drug substance, composition, formulation, or specific therapeutic uses).
- Whether the question refers to the last patent to expire, or the earliest one that blocks generic entry.
- Any regulatory exclusivity that may extend market protection even after patents expire (e.g., regulatory exclusivity categories), which requires knowing the approval pathway and dates.
How to get a precise answer quickly (what to share)
If you provide any of these, the expiry can be pinned down accurately:
- Tenapanor’s brand name used in the US and the reference drug/label (if you have it).
- The US patent number(s) you’re concerned about (or a link to the patent list/Orange Book entry).
- The Orange Book listing date or the “Patent” and “Exclusivity” sections text for tenapanor.
How “expiry” can differ from what people mean
Even when the patent expiry date is known, “when generics can launch” may depend on:
- Which patent is the controlling one (the last-to-expire vs. the one asserted for protection).
- Patent term adjustments (PTA) and any pediatric exclusivity (if applicable), which can change the effective expiry.
- Court stays or injunctions from litigation, which can delay entry beyond the paper expiry.
Sources
No source material was provided with patent numbers or an Orange Book listing to cite.